Erratum to: Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction – a randomised placebo-controlled trial (KARE): study protocol

Erratum

In the original publication [1] the last sentence under the paragraph “Adverse event management” not correct. The correct version can be found here:

“SAEs that occur between trial entry and up to 28 days after completion of the study drug will be reported”.